Health Care · Wholesale-Drugs, Proprietaries & Druggists' Sundries

NUS NU SKIN ENTERPRISES, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1021561103 filings
Russell 2000

NUS at a glance

NU SKIN ENTERPRISES, INC. (NUS, SEC CIK 1021561) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), NU SKIN ENTERPRISES, INC. (NUS) reported revenue of $1.5 billion (down 14.3% from FY2024) and net income of $160.2 million. Diluted EPS was $3.18.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding NU SKIN ENTERPRISES, INC. (NUS) shares worth $87.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Nathanson Laura on May 11, 2026 of 2,676 shares at $6.73 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.5B
−14.3% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
29 funds
$87.1M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the 2025 Form 10-K risk factors

Management Discussion & Analysis

  • Q3 revenue $311.0M, down 14.6% YoY from $364.2M
  • Gross margin 65.0% vs 70.5% YoY, net loss $(0.7)M vs $17.1M net income
  • Best segment: Manufacturing revenue $56.8M, up 19.3%; worst: Rhyz Other revenue $1.6M, down 59.6%
  • Cash $166.6M vs $239.8M at December 31; operating cash flow $(1.4)M vs $63.7M
  • Near-term headwinds: macroeconomic softness, declining customer metrics, India model simplification before first-half 2027 launch, tariff uncertainty

AI summary of the NUS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Nu Skin’s third-quarter and nine-month results for periods ended September 30, 2026
  • Exhibit 99.1 contains the financial figures and management commentary investors need for performance assessment

Item EX-99.1: Item EX-99.1

  • Q3 revenue $311.0M, down 14.6% year over year, with Nu Skin segment down 19.2%
  • Customer base fell 18% to 609,469, while paid affiliates declined 10% and sales leaders 13%
Filed Aug 21, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Justin Keisel began a medical leave August 17, 2026, creating temporary leadership uncertainty for Global Sales
  • COO and Chief Legal Officer Chayce Clark will lead Keisel’s organization during the absence
Filed Aug 10, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $320.1M, down 17.1% year over year; broad weakness across Nu Skin and Rhyz segments
  • GAAP EPS $(5.14), including $78.9M impairment and $167.5M deferred-tax valuation allowance; adjusted EPS $0.20

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Nu Skin’s three- and six-month results ended June 30, 2026
  • Investor-relevant financial details are contained in Exhibit 99.1

AI summaries of NUS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NUS

Don't miss the next NUS filing

  • Alerts as it files. A push when NUS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NUS, by share count.
  • Ask anything. An AI agent that reads every NUS filing and answers with sources.

NUS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
WOODBURY EDWINA DASep 9, 2026$4.85
WOODBURY EDWINA DAJun 10, 2026$5.43
Nathanson LauraSellMay 11, 2026$6.73
WOODBURY EDWINA DAMar 11, 2026$7.31
Keisel Justin SAMar 6, 2026-
Clark Chayce DavidAMar 6, 2026-
Hatchett Steven KeithAMar 6, 2026-
Thomas James DAMar 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.7B$1.5B
Gross Profit-$1.2B$1.0B
Operating Income--$151.6M$65.8M
Net Income--$146.6M$160.2M
Gross Margin-68.2%69.4%
Op. Margin--8.8%4.4%
Net Margin--8.5%10.8%
Balance Sheet
Total Assets$1.8B$1.5B$1.4B
Equity$822.0M$651.5M$805.2M
ROE--22.5%19.9%
Per Share
EPS-$-2.95$3.18
Cash Flow
Operating CF-$111.7M$80.3M
CapEx-$41.6M$34.3M

Source: XBRL data in NU SKIN ENTERPRISES, INC. (NUS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NUS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NUS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$87.1M
Q2 202629$103.0M
Q1 202629$138.8M
Q4 202527$181.5M
Q3 202528$239.7M
Q2 202528$159.2M
Q1 202526$123.3M
Q4 202421$90.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 217 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NUS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
4Sep 10, 2026--
8-KAug 21, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Jun 11, 2026--
8-KMay 29, 2026Analysis
4May 12, 2026-
8-KMay 8, 2026Analysis
10-QMay 8, 2026Analysis
8-KMay 7, 2026Analysis
8-KMar 27, 2026--
8-KMar 20, 2026--
4Mar 12, 2026--
4Mar 9, 2026--
4Mar 9, 2026--
4Mar 9, 2026--
4Mar 9, 2026--
8-KMar 9, 2026Analysis-
4Mar 9, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--

Related Health Care companies

All Health Care →

NUS SEC filings: frequently asked questions

Which institutions hold NUS stock?

As of September 30, 2026, the largest NU SKIN ENTERPRISES, INC. (NUS) holders among the 13F filers tracked by SignalX were BlackRock ($19.1 million), Vanguard Capital Management LLC ($9.5 million), Vanguard Portfolio Management LLC ($8.0 million), Renaissance Technologies LLC ($7.0 million), Dimensional Fund Advisors ($6.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NUS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), NU SKIN ENTERPRISES, INC. (NUS) reported revenue of $1.5 billion (down 14.3% from FY2024) and net income of $160.2 million. Diluted EPS was $3.18. The figures come from the XBRL data in the 10-K.

What did NUS report in its latest 8-K?

NU SKIN ENTERPRISES, INC. (NUS) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Nu Skin’s third-quarter and nine-month results for periods ended September 30, 2026.

What are the latest NUS SEC filings?

NU SKIN ENTERPRISES, INC. (NUS) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 10, 2026.

What is NUS's SEC CIK number?

NU SKIN ENTERPRISES, INC. (NUS)'s SEC Central Index Key (CIK) is 1021561. EDGAR lists every NUS filing under that number.

Ask anything about NUS

The research agent reads NUS's filings, financials, insider trades and 13F holders, then answers with sources.